secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2023-07-12T23:59:59+00:00
Accession:  0000950170-23-032604
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx appoints Howard Horn as CFO and EVP, Corporate Strategy effective Oct 16, 2023
--------------------------------------------------------------------------------

- Howard Horn appointed CFO and EVP, Corporate Strategy effective October 16, 2023.
- Base salary of $590,000/year, target bonus 50%, sign-on bonus of $60,000.
- Equity award with target value of $6 million: 50% options, 50% RSUs vesting over 4 years.
- Previously CFO at Vir Biotechnology (2017-2023) and held finance roles at Biogen.
- Will lead finance, accounting, corporate strategy, and investor relations at Ultragenyx.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023032604/0000950170-23-032604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023032604/rare-20230712.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-032604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer